Psychiatry Research
Volume 120, Issue 2 , Pages 115-124 , 30 September 2003

Hypothalamic–pituitary–adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine (‘ecstasy’) use history: correlation with dopamine receptor sensitivity

  • Gilberto Gerra

      Affiliations

    • Addiction Research Centre, Centro Studi Farmacotossicodipendenze, Ser.T., A.U.S.L., Via Spalato 2, Parma 43100, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0521-393125; fax: +39-0521-393150
    • ,
  • Sara Bassignana

      Affiliations

    • Department of Pharmacology, University of Parma, Parma, Italy
    • ,
  • Amir Zaimovic

      Affiliations

    • Addiction Research Centre, Centro Studi Farmacotossicodipendenze, Ser.T., A.U.S.L., Via Spalato 2, Parma 43100, Italy
    • ,
  • Gabriele Moi

      Affiliations

    • Addiction Research Centre, Centro Studi Farmacotossicodipendenze, Ser.T., A.U.S.L., Via Spalato 2, Parma 43100, Italy
    • ,
  • Monica Bussandri

      Affiliations

    • Addiction Research Centre, Centro Studi Farmacotossicodipendenze, Ser.T., A.U.S.L., Via Spalato 2, Parma 43100, Italy
    • ,
  • Rocco Caccavari

      Affiliations

    • Addiction Research Centre, Centro Studi Farmacotossicodipendenze, Ser.T., A.U.S.L., Via Spalato 2, Parma 43100, Italy
    • ,
  • Francesca Brambilla

      Affiliations

    • Centro di Psiconeuroendocrinologia, University of Milan, Milan, Italy
    • ,
  • Enzo Molina

      Affiliations

    • Department of Pharmacology, University of Parma, Parma, Italy

Received 18 March 2002 ,Revised 4 December 2002 ,Accepted 16 December 2002.

References 

  1. Bellomo RD. Aspetti di polizia scientifica. In: Atti del Seminario Studi sui Derivati Amfetaminici. Rome: Italian Ministry of Interior; 1995;p. 43–48
  2. Black DW, Noyes R, Pfohl B, Goldstein RB, Blum N. Personality disorder in obsessive-compulsive volunteers, well comparsion subjects, and their first-degree relatives. American Journal of Psychiatry. 1993;150:1226–1232
  3. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. Journal of Psychoactive Drugs. 2000;32(Suppl. i–iv):1–112
  4. Buss AH, Durkee A. An inventory for assessing different kinds of hostility. Journal of Consulting Psychology. 1957;21:343–349
  5. Castrogiovanni P, Maremmani I, Di Muro A. Aggressive behaviour and hostility in depression: clinical aspects. In:  Placidi GF,  Dell'Osso L,  Nisticò G,  Akiskal HS editor. Recurrent Mood Disorders. Berlin Heidelberg: Springer-Verlag; 1993;p. 51–65
  6. Cloninger CR. A systematic method for clinical description and classification of personality variants. Archives of General Psychiatry. 1987;44:573–588
  7. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997;386(6627):824–827
  8. Fletcher PJ, Azampanah A, Korth KM. Activation of 5-HT(1B) receptors in the nucleus accumbens reduces self-administration of amphetamine on a progressive ratio schedule. Pharmacology, Biochemistry and Behaviour. 2002;71(4):717–725
  9. Frei E, Gamma A, Pascual-Marqui R, Lehmann D, Hell D, Vollenweider FX. Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). Human Brain Mapping. 2001;14(3):152–165
  10. Gabel S, Stadler J, Bjorn J, Shindledecker R. Homovanillic acid and dopamine-beta-hydroxylase in male youth: relationships with paternal substance abuse and antisocial behavior. American Journal of Drug and Alcohol Abuse. 1995;21(3):363–378
  11. Gerra G, Zaimovic A, Chittolini B, Giucastro G, Folli F, Maestri D, et al. Neurotransmitter-hormonal responses to psychological stress in peripubertal subjects: relationship to aggressive behavior. Life Sciences. 1998;62(7):617–625
  12. Gerra G, Zaimovic A, Giucastro G, Maestri M, Monica C, Sartori R, et al. Serotonergic function after (±)3, 4-methylene-dioxy-methamphetamine (MDMA, ‘ecstasy’) in humans. International Clinical Psychopharmacology. 1998;13:1–9
  13. Gerra G, Zaimovic A, Zambelli U, Timpano M, Neri E, Marzocchi GF, et al. Long-lasting effects of ±(3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biological Psychiatry. 2000;47:127–136
  14. Gerra G, Zaimovic A, Giusti F, Delsignore R, Raggi MA, Laviola G, et al. Experimentally-induced aggressive behaviour in subjects with 3,4-methylenedioxy-methanfetamine (MDMA; ‘ecstasy’) use history; psychobiological correlates. Journal of Substance Abuse. 2001;13:471–491
  15. Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R, et al. Effects of (±)3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans. Behavioural Brain Research. 2002;134:403–410
  16. Goeders NE. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology. 2002;27(1–2):13–33
  17. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behavioral Brain Research. 1996;73(1–2):103–107
  18. Grossi G, Ahs A, Lundberg U. Psychological correlates of salivary cortisol secretion among unemployed men and women. Integrative Physiological Behavioral Science. 1998;33(3):249–263
  19. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  20. Hathaway, S.R., McKinley, J.C., 1989. Minnesota Multiphasic Personality Inventory-2. Manual, University of Minnesota, Minneapolis
  21. Kariyawasam SH, Zaw F, Handley SL. Reduced salivary cortisol in children with comorbid attention deficit hyperactivity disorder and oppositional defiant disorder. Neuroendocrinology Letters. 2002;23(1):45–48
  22. Kirschbaum C, Diedrich O, Gehrke J, Wüst S, Hellhammer DH. Cortisol and behavior. ‘The Trier challenge test (TMCT)’: first evaluation of a new psychological sress test. In:  Ehlers A,  Fiegenbaum W,  Florin I,  Margraf J editor. Perspectives and Promises of Clinical Psychology. New York: Plenum; 1992;p. 67–75
  23. Kirschbaum C, Pirke KM, Hellhammer DH. The ‘Trier Social Stress Test’—a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28:76–88
  24. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology. 2000;55(2):294–296
  25. Liechti ME, Geyer MA, Hell D, Vollenweider FX. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol or ketanserin. Neuropsychopharmacology. 2001;24(3):240–252
  26. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA (‘ecstasy’) after haloperidol pretreatment in healthy humans. European Neuropsychopharmacology. 2000;10(4):289–295
  27. Majewska MD, Wilkins J. Low plasma levels of DHEAS as markers for refractory cocaine dependence. Neuropsychopharmacology. 2000;23:S46; [Abstract]
  28. Majewska MD. HPA axis and stimulant dependence: an enigmatic relationship. Psychoneuroendocrinology. 2002;27(1–2):5–12
  29. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. Journal of Pharmacology and Experimental Therapeutics. 1999;290(1):136–145
  30. Mayerhofer A, Kovar KA, Schmidt WJ. Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neuroscience Letters. 2001;308(2):99–102
  31. McCann BS, Carter J, Vaughan M, Raskind M, Wilkinson CW, Veith RC. Cardiovascular and neuroendocrine responses to extended laboratory challenge. Psychosomatic Medicine. 1993;55:497–504
  32. Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology. 1995;20(4):365–375
  33. Okuse S, Anzai T. Psychosomatic aspects of stress. Rinsho Byori. 1992;40(3):234–240
  34. Parrott AC. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology. 2001;16(8):557–577
  35. Rao U, Ryan ND, Dahl RE, Birmaher B, Rao R, Williamson DE, et al. Factors associated with the development of substance use disorder in depressed adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38(9):1109–1117
  36. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (‘ecstasy’). Science. 2002;297(5590):2185–2187
  37. Spitzer, R.L., Williams, J.B.W., Gibbon, M., First, M.B. 1990, Structured Clinical Interview for DSM-III-R First published by American Psychiatric Press, Washington D.C. and London, England
  38. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. Journal of Psychopharmacology. 1999;13(4):337–345
  39. Volpi R, Caffarra P, Scaglioni A, Boni S, Saginario A, Chiodera P, et al. Defective 5-HT1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology. 1997;35(2):79–83
  40. Wilkins J, Van Gorp W, Hinken C, Welch B, Wheatley S, Plotkin D, et al. Relapse to cocaine use may be predicted in early abstinence by low plasma dehydroepiandrosterone. NIDA Research Monograph. 1997;174:183

PII: S0165-1781(03)00175-6

doi: 10.1016/S0165-1781(03)00175-6

Psychiatry Research
Volume 120, Issue 2 , Pages 115-124 , 30 September 2003

Article Tools

* Image Usage & Resolution